Breast Cancer

Breaking News: Sellas Announces Promising Data on NeuVax in Combination with Herceptin in HER2 1+/2+ Breast Cancer

NeuVax + Herceptin may provide a clinically meaningful benefit to breast cancer patients with low to intermediate HER2-expression.

If Your Bra Could Talk

Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG
If your bra could talk, do you know what she would tell you?

Helping Patients Create a Legacy

Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG
I wanted to share with you my weekend experience at the Young Survival Coalition Summit. I was asked to conduct a 4-hour workshop for young women with stage IV breast cancer. The workshop title I was given was “Building Your Legacy.”

Breast Cancer Awareness Month

Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG
It’s here! October—National Breast Cancer Awareness Month—although honestly, this type of cancer is very much in the public eye throughout the year. Breast cancer survivors, those at risk, and families who have lost a loved one to this disease have made it their charge to keep a pink theme year round.

Insights into Navigation: Genetics and Breast Cancer Surgery

Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG
If your newly diagnosed patient meets the criteria for warranting a genetics consultation and testing, do the necessary paperwork to have it happen BEFORE surgery!

Navigators Should Make Women Aware of Breast Density’s Effect on Cancer Risk

Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG
Despite research being conducted and confirmed on the significance of breast density, most women don’t know that having dense breasts increases their risk for breast cancer and reduces a mammogram’s ability to detect cancer, according to a University of Virginia (UVA) School of Medicine study.

Seasoned Navigator: A Case Study on Care Transitions in Genomic Testing and Timely Treatment Decision-Making

Cheryl Bellomo, MSN, RN, HON-ONN-CG, OCN,Deborah Christensen, RN, BSN, HNB-BC,Tricia Strusowski, RN, MS
Along with the diagnosis of breast cancer comes many decisions regarding treatment options. Oncotype DX, a genomic/gene expression assay, provides quantitative assessment of chemotherapy benefit and risk of distant recurrence in early-stage estrogen receptor–positive (ER+), HER2/neu-negative breast cancer to assist in developing individualized treatment plans.

Educating and Supporting Breast Cancer Patients in Making Decisions about Treatment

Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG
There are various points along the journey that we, as nurse navigators, need to be at the side of our patients when critical treatment decisions are being made. This is something that you do every day, and are more than familiar with regarding your role in education and support as it relates to this type of decision making.

Supporting and Empowering Breast Cancer Patients to Have No Treatment Regrets Years Later

Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG
Commonly when a breast cancer nurse navigator is educating and supporting a patient, the time period is focused on the point of diagnosis through their acute treatment. How do we really know if the patients, now as survivors, believe the right decisions were made regarding treatment options? How do we know they felt the decisions were made with their active input? Were they confident in their choices?

Navigating the Underserved and Minority Breast Cancer Patients— Challenges and Solutions

When we are discussing minorities, we are usually referring to African American, Hispanic/Latino, and the American Indian/Alaska Natives in our society. In addition, underserved women are those who have a decreased income and socioeconomic status, lower education levels, commonly lack health insurance, and have limited access to healthcare in general. These patient populations are particularly challenging when facing the diagnosis and treatment of breast cancer.